Belzutifan is used to treat VHL-associated RCC. It’s a HIF-2α inhibitor that helps by cutting down on tumor hypoxia signaling. You can get it in 40 mg tablets.
The usual amount to take each day is 120 mg. The tablets come in bottles with 90 in each. Each dose, which is 120 mg, means taking three of those 40 mg tablets.
